Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

Table 2 Tyrosine kinase inhibitors of the epidermal growth factor receptor tyrosine kinase family

Inhibitor	Tyrosine kinase target	Neoplasm(s) targeted	Clinical status
Gefitinib (Iressa, ZD1839)	EGFR	Lung, breast	Approved
Erlotinib (Tarceva, OSI774)	EGFR	Lung	Approved
Lapatinib (Tykerb, GW-572016)	ErbB1, ErbB2	Breast, RCC, gastric, HN, NSCLC	Approved
Canertinib (CI-1033)	EGFR, ErbB2, ErbB3, ErbB4	Breast, NSCLC, HN	Phase I/II
NVP-AEE788	EGFR, ErbB2, VEGFR	Solid tumors	Phase II
XL647	EGFR, ErbB2, VEGFR, EphB4	Cancer	Phase I
PKI-166	EGFR, ErbB2	Adv solid tumors	Phase I
SU-11464	ErbB2	Cancer	Preclinical
EKB-569	EGFR, ErbB2	NSCLC, colorectal, solid	Phase II
AG1478	EGFR	Nasopharyngeal	Preclinical
CP724,714	ErbB2	Breast, adv solid tumors	Phase I/II
PD-158780	EGFR, ErbB2, ErbB4	Cancer	Preclinical
CP-654577	ErbB2	Breast	Preclinical
BIBW2992	EGFR, ErbB2	NSCLC, HN, breast	Phase II
HKI-272	ErbB2	Breast, solid tumors	Phase I/II
CL-387,785	EGFR, ErbB2	Cancer	Preclinical
CP358,774	EGFR	HN, ovarian, breast	Phase II
MP 412	EGFR, ErbB2	NSCLC, breast, HN, pancreatic, prostate	Phase I

Trk: Nerve growth factor receptor tyrosine kinase; PKC: Protein kinase C; RCC: Renal cell carcinoma; HN: Head and neck cancer; NSCLC: Non small cell lung cancer; EGFR: Epidermal growth factor receptor.